ADPT

Over the past six months, Adaptive Biotechnologies' stock has performed strongly, surging 76% and gaining 68% over the past year, with the stock price reaching $28.77 as of September 29, 2026. Key events include Q1 2026 revenue of $70.9 million (up 35% year-over-year) and Q2 2026 revenue of $71.6 million (up 22% year-over-year), despite an adjusted loss per share. The company updated its full-year 2026 MRD revenue guidance and saw its clonoSEQ test referenced in updated NCCN Guidelines® for Multiple Myeloma, leading to raised price targets from analysts. ADPT participated in major healthcare conferences, and in October 2026, executives sold shares under Rule 10b5-1 plans, which is noted as a watch item. In June 2026, the company announced plans to separate its Immune Medicine and MRD business units and proposed an offering of convertible senior notes due 2031.